143 results
8-K
EX-99.1
KA
Kineta Inc
15 May 24
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4:03pm
research services provided under the Merck Neuromuscular License Agreement, which we completed in June 2023.
Research and development (R&D) expense: R … )
Three Months Ended March 31,
Revenues:
Collaboration revenues
Total revenues
Operating expenses:
Research and development
General and administrative
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
payment. Revenues in 2022 were due to research and development services from the Genentech Option and License Agreement, which was terminated in December … 2022, and also due to services provided under a grant that was concluded in December 2022.
Research and development (R&D) expense: R&D expenses were
424B3
42ir8hpjz
13 Nov 23
Prospectus supplement
5:28pm
8-K
EX-99.1
3re6325s l85ps3sc53c
3 Nov 23
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:02pm
424B5
vfkeme
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
EX-99.1
t42y8d
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
cty9tf5bb 2at
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
EX-99.1
rgntnl w2z8lnlva3qcl
28 Jun 23
Departure of Directors or Certain Officers
7:00am
424B3
rso89rl3kd115bi81lni
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-99.1
qzfaij
11 May 23
Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update
5:20pm
424B5
j075phs yg
21 Apr 23
Prospectus supplement for primary offering
5:14pm